Lilly to acquire Alnara

Eli Lilly and Co. (NYSE:LLY) will acquire Alnara Pharmaceuticals Inc. (Cambridge, Mass.) for an undisclosed amount. Alnara's lead compound is liprotamase, a non-porcine pancreatic enzyme replacement therapy under FDA review to treat exocrine pancreatic insufficiency (See BioCentury, Oct. 26, 2009). ...